EUCTR2010-018619-14-DE
Active, not recruiting
Not Applicable
Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus - Lira-Vasc-001
ikfe GmbH0 sitesFebruary 16, 2010
ConditionsType 2 Diabetes Mellitus
DrugsVictoza®
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Type 2 Diabetes Mellitus
- Sponsor
- ikfe GmbH
- Status
- Active, not recruiting
- Last Updated
- 13 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Diabetes Mellitus type 2
- •2\. HbA1c \= 5\.5% and \= 7\.0%
- •3\. Treatment with Metformin (daily dose 500 – 3000 mg monotherapy, the past 3 months)
- •4\. Age 30 – 65 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •1\. Pre\-treatment with PPAR gamma agonists or DPP IV inhibitors or GLP\-1 analogues within the last three months
- •2\. History of type 1 Diabetes Mellitus
- •3\. No full legal mental and physical ability to give informed consent
- •4\. Uncontrolled hypertension (systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 90 mmHg)
- •5\. Anamnestic acute and chronic infections
- •6\. Anamnestic history of epilepsy
- •7\. Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures
- •8\. History of severe or multiple allergies
- •9\. Treatment with any other investigational drug within 3 months before trial entry
- •10\. Progressive fatal disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT01208012ikfe-CRO GmbH44
Active, not recruiting
Phase 1
Effect of liraglutide on vascular inflammation in type-2 diabetesEUCTR2016-001523-31-DKSteno Diabetes Center Copenhagen100
Completed
Phase 4
Differences in Endothelial Function Amongst Sitagliptin and Liraglutide UsersDIABETES Mellitus Type 2 Not Well ControlledNCT01785043Anna Cruceta13
Completed
Not Applicable
Effect of alogliptin on endothelial dysfunction induced by postprandial hypelipidemiaJPRN-UMIN000008296Department of Cardiovascular Medicin,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama30
Completed
Not Applicable
Effect of alogliptin on endothelial dysfunction induced by hyperlipidemiahaelthy subjects patients wiht coronary artery disease subjects wiht metabolic symdromeJPRN-UMIN000008297Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences60